Overview
MCRB market data
Price History
MCRB price chart
Valuation & Profitability
- P/E (TTM)
- 7.89 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.64 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.26 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,192.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.59 – $29.98 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $44.9M · P/B 3.04 · P/S 23.86.
Company News
Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And UnitsBenzinga · Aug 13, 2026, 9:21 PM
Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K EstimateBenzinga · Aug 5, 2026, 11:29 AM
8-K filing — Seres Therapeutics, Inc. (MCRB)SEC EDGAR · Aug 5, 2026, 11:05 AM
Seres Therapeutics Posts Early Data for Cancer Therapy ComplicationBenzinga · Jul 8, 2026, 5:10 PM
Seres Therapeutics Announces Top-Line Results From An IST Evaluating SER-155 In Patients With irEC; SER-155 Well Tolerated, With No Drug-Related Serious Adverse Events ObservedBenzinga · Jul 8, 2026, 11:10 AM
Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related EnterocolitisBenzinga · Jun 25, 2026, 11:30 AM
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jun 23, 2026, 1:50 PM
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12Benzinga · Jun 23, 2026, 11:35 AM
Seres Therapeutics Announces Balance Sheet Transactions; Nestle To Pay Company $25 M In Two Installments To Buy Out Sales Milestone PaymentsBenzinga · Jun 5, 2026, 11:05 AM